FDA Approved: DOXORUBICIN HYDROCHLORIDE — Supplemental Application (Zydus Lifesciences Limited)

View source ↗

Summary

FDA approved a supplemental application for doxorubicin hydrochloride from Zydus Lifesciences Limited, updating the labeling for the product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Bladder Cancer
• Breast Cancer
• Hodgkin Lymphoma
• Non-hodgkin Lymphoma
• Ovarian Cancer
• Soft Tissue Sarcoma

Drugs mentioned

• DOXORUBICIN HYDROCHLORIDE (Doxorubicin hydrochloride)

Snippet

SUPPL AP for DOXORUBICIN HYDROCHLORIDE (DOXORUBICIN HYDROCHLORIDE)